Blockade of IL-23: What is in the Pipeline?

Tommaso Lorenzo Parigi; Marietta Iacucci; Subrata Ghosh

doi:10.1093/ecco-jcc/jjab185

Blockade of IL-23: What is in the Pipeline?

Tommaso Lorenzo Parigi
, Marietta Iacucci
, Subrata Ghosh

Research output: Contribution to journal › Article › peer-review

Abstract

Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.

Original language	English
Pages (from-to)	II64-II72
Journal	Journal of Crohn's and Colitis
Volume	16
DOIs	https://doi.org/10.1093/ecco-jcc/jjab185
Publication status	Published - 1 Apr 2022

Keywords

anti-IL23 monoclonal antibodies
Crohn's disease
interleukin 12
Interleukin 23
ulcerative colitis

Access to Document

10.1093/ecco-jcc/jjab185

Cite this

@article{8a633d571fbc4e60b8f2e7de6789dc86,

title = "Blockade of IL-23: What is in the Pipeline?",

abstract = "Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.",

keywords = "anti-IL23 monoclonal antibodies, Crohn's disease, interleukin 12, Interleukin 23, ulcerative colitis",

author = "Parigi, \{Tommaso Lorenzo\} and Marietta Iacucci and Subrata Ghosh",

note = "Publisher Copyright: {\textcopyright} 2022 The Author(s).",

year = "2022",

month = apr,

day = "1",

doi = "10.1093/ecco-jcc/jjab185",

language = "English",

volume = "16",

pages = "II64--II72",

journal = "Journal of Crohn's and Colitis",

issn = "1873-9946",

publisher = "Oxford University Press",

}

TY - JOUR

T1 - Blockade of IL-23

T2 - What is in the Pipeline?

AU - Parigi, Tommaso Lorenzo

AU - Iacucci, Marietta

AU - Ghosh, Subrata

PY - 2022/4/1

Y1 - 2022/4/1

N2 - Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.

AB - Interleukin 23 [IL-23] plays a key role in the pathogenesis of both Crohn's disease [CD] and ulcerative colitis [UC], promoting a Th17 cell-related immune response. The combined blockade of IL-23 and IL-12 with ustekinumab has been demonstrated to be safe and effective in the treatment of inflammatory bowel disease [IBD]. Studies on preclinical models and observations of other immune-mediated diseases, such as psoriasis, suggest that the selective inhibition of IL-23 could be beneficial in IBD. Four monoclonal antibodies [risankizumab, mirikizumab, brazikumab and guselkumab] are currently in advance clinical trials for either CD or UC. In this review, we provide an overview of the main results from published studies of selective anti IL-23 agents.

KW - anti-IL23 monoclonal antibodies

KW - Crohn's disease

KW - interleukin 12

KW - Interleukin 23

KW - ulcerative colitis

UR - https://www.scopus.com/pages/publications/85130043437

U2 - 10.1093/ecco-jcc/jjab185

DO - 10.1093/ecco-jcc/jjab185

M3 - Article

C2 - 35553666

AN - SCOPUS:85130043437

SN - 1873-9946

VL - 16

SP - II64-II72

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

ER -

Blockade of IL-23: What is in the Pipeline?

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this